HCQ

Infectious Disease Specialist Calls Campaign against Repurposed Drugs in COVID-19 a ‘Great Hypocrisy’

Retrieved on: 
Thursday, March 21, 2024
Vanderbilt University, COVID, HCQ, Rheumatoid arthritis, Infection, Azithromycin, Lupus, Diabetes, COVID-19, Patient, Knowledge, Journal, Mortality, Addiction, Hydroxychloroquine, AAPS, Dysautonomia, Physician, Ivermectin, IVM, Pharmaceutical industry

Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.

Key Points: 
  • Just before the death-knell announcement, Dr. Hoffman notes, substantial evidence favoring early use of HCQ had been submitted for publication by Dr. Harvey Risch of Yale.
  • “In fact, all evidence is inherently flawed.”
    Dr. Hoffman points out how inconsistencies and double standards reveal the FDA’s hypocrisy regarding HCQ and ivermectin (IVM).
  • Paxlovid, he writes, has not been shown to be effective in hospitalized COVID patients, whereas the “flawed” study of HCQ demonstrated a greater than 60 percent benefit in reducing mortality.
  • “There is in fact a corpus of knowledge about the use of HCQ, IVM, and other off-label drugs, for example, at c19hcq.org, c19IVM.org18, and earlycovidcare.org,” Dr. Hoffman states.

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Retrieved on: 
Wednesday, January 24, 2024
Magnetic resonance, Antigen presentation, Patient, Chronic obstructive pulmonary disease, IP, MRI, Inflammatory bowel disease, Pharmacokinetics, Rheumatoid arthritis, Asthma, Fatigue, Joint stiffness, IBD, API, HCQ, Cannabidiol, COPD, Quality of life, Plasma, NDA, FDA, Pain, Lupus erythematosus, Inflammation, Biomarker, Epilepsy, Magnetic resonance imaging, Hydroxychloroquine, Pharmaceutical industry

The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.

Key Points: 
  • The primary endpoint of the double-blind, Phase 2 clinical trial is pain and function relative to baseline determined via the score on the RAPID-3 assessment at 24 weeks.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said; “Commencing dosing in the Phase 2 clinical trial in patients with RA is an exciting milestone for the development of IHL-675A.
  • Millions of people are affected by pain associated with rheumatoid arthritis despite the available treatment options.
  • Overview of Results from Phase 1 Clinical Trial Assessing Tolerability, Safety, and Pharmacokinetics of IHL-675A in Healthy Volunteers
    In 2022 and 2023, Incannex undertook a Phase 1 clinical trial to assess the safety, tolerability, and pharmacokinetics of IHL-675A.

Accountability Needed for COVID Debacle, according to the Journal of American Physicians and Surgeons

Retrieved on: 
Wednesday, December 13, 2023
HCQ, AAPS, CDC, Food, Sudden death, Physician, Messenger, FDA, Mortality, Ivermectin, COVID, COVID-19, Bangladesh Technical Education Board, Presidency of Donald Trump, NIH, Patient, Hydroxychloroquine, Journal, Pharmaceutical industry

Dr. Hatfill served as a medical/scientific advisor to the Executive Office of the President during the Trump Administration.

Key Points: 
  • Dr. Hatfill served as a medical/scientific advisor to the Executive Office of the President during the Trump Administration.
  • Early results from overseas were promising, and by July 2020, early-use HCQ had been shown to reduce COVID hospital mortality by more than 50 percent.
  • Investigation requires legal experts, forensic accountants, scientific experts, and physicians, Dr. Hatfill concludes.
  • The Journal of American Physicians and Surgeons is published by the Association of American Physicians and Surgeons (AAPS), a national organization representing physicians in all specialties since 1943.

Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Retrieved on: 
Thursday, July 13, 2023
Active ingredient, Hydroxychloroquine, RA, Inflammation, Joint stiffness, NDA, Quality of life, ASX, Biomarker, HCQ, Fatigue, MRI, Nature, Rheumatoid arthritis, API, VIC, FDA, Function, Safety, Cannabidiol, Disease, Pharmaceutical industry, Fine chemical, Birth control, Medical device, Avance, Pain, CBD, Patient

MELBOURNE, Australia, July 13, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’), a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has received approval from Bellberry Human Research Ethics Committee (‘HREC’) for the lead site, Emeritus Research, Camberwell, Victoria, for its Phase 2 clinical trial. The trial is pivotal in nature and will assess the efficacy of IHL-675A, its proprietary anti-inflammatory combination drug product, in patients with rheumatoid arthritis (‘RA’).

Key Points: 
  • Incannex has received approval from HREC for the lead site, Emeritus Research, Camberwell, VIC for the Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis.
  • The Phase 2 trial follows a successful Phase 1 trial where IHL-675A was observed to be well tolerated and safe.
  • This trial will be managed by Avance Clinical, an Australian and US CRO, who will engage 8-10 clinical trial sites across Australia and New Zealand, recruiting 128 patients in total.
  • Incannex Chief Scientific Officer Dr Mark Bleackley said: “HREC approval for the Phase 2 clinical trial is a key step in the development of IHL-675A for treatment of pain and reduced function associated with rheumatoid arthritis.

Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A

Retrieved on: 
Tuesday, May 2, 2023
Tmax, Comparison, Half-life, Somnolence, Pharmacokinetics, ASX, Cmax, Inflammation, Abdominal pain, HCQ, Inflammatory bowel disease, Plasma, Defecation, Incidence, Dizziness, Appendix, Headache, Safety, Rheumatoid arthritis, Fatigue, Pharmaceutical industry, Hydroxychloroquine, Cannabidiol, CBD

The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).

Key Points: 
  • The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).
  • Three cohorts of 12 participants (n = 36) received either IHL-675A, CBD or HCQ and the clinical assessments were identical across the three arms of the trial.
  • The trial was conducted by CMAX Clinical Research in Adelaide, South Australia and managed by Avance Clinical.
  • Incannex Chief Scientific Officer Dr Mark Bleackley said: “The results from the Phase 1 trial are a critical milestone in the development of IHL-675A.

Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis

Retrieved on: 
Tuesday, February 28, 2023
Clinical trial, HCQ, Safety, Active ingredient, Arthritis, Quality of life, Inflammation, ASX, Disease, Hydroxychloroquine, Biomarker, Research, Function, Magnetic resonance imaging, MRI, NDA, RA, Rheumatoid arthritis, Human, Fatigue, Joint stiffness, API, Pharmacokinetics, Pharmaceutical industry, Birth control, Medical imaging, Patient, CBD, Avance, Pain

SYDNEY, Australia, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has commenced a Phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients with rheumatoid arthritis (‘RA’). IHL-675A is a proprietary fixed dose combination drug comprising cannabidiol (CBD) and hydroxychloroquine (‘HCQ’).

Key Points: 
  • Incannex has commenced a Phase 2, Blinded, Placebo Controlled Clinical Trial to Determine the Safety and Effect on Pain and Function of IHL-675A in Patients with Rheumatoid Arthritis.
  • The trial will assess the effect of IHL-675A on pain and function by utilising patient reported outcomes, disease scores and inflammatory biomarker analysis over a 24-week period.
  • There will be an option for trial participants to participate in an extension study following the trial.
  • This Phase 2 clinical trial follows the successful Phase 1 clinical trial whereby IHL-675A was observed to be well tolerated, with no adverse events of concern.

Proactive news headlines including Radiopharm Theranostics, AuTECO Minerals, Lake Resources and Incannex Healthcare

Retrieved on: 
Tuesday, October 18, 2022
Citadel, La, Research report, COVID, Nickel, NASDAQ, Program, Lithium, WSR, University, CAV, OTC, CPM, RC, KTA, Technology, HCQ, Severe acute respiratory syndrome coronavirus 2, AUT, RCE, SPP, Zinc, GLOBE, TBN, Imperial College London, RAD, Beetaloo, CRO, Cannabidiol, AON, Risk, AAU, Wilki, Silver, Tourism, OTCQB, Newcrest Mining, UWA, ASX, MDMA, NIS, Rio Tinto, Brain, Patient, Paterson, Proactivity, Hydroxychloroquine, ARN, JV, Acquisition, Safety, Gold, Yilgarn Craton, COVID-19, EMD, Pharmaceutical industry, Oil, Iron ore, Mining, Rare-earth element, Crux, Science, CBD

Click here

Key Points: 
  • Click here
    Regener8 Resources NL has embarked on its first-ever field campaign at the Kookynie Gold Project near Leonora in WA.
  • Click here
    Golden Rim Resources Ltd (ASX:GMR) has identified additional gold targets from a geophysical survey program at the Kada Gold Project in Guinea, West Africa.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials

Retrieved on: 
Thursday, October 13, 2022
TBI, COPD, Rheumatoid arthritis, Arthritis, ASX, Bronchitis, IND, HCQ, Cannabinoid, NASDAQ, U.S. FDA, Patient, OSA, Asthma, Traumatic brain injury, Inflammation, Nasdaq, Addiction, Private Securities Litigation Reform Act, Australian Securities Exchange, Mouse, Trial of the century, Company, American depositary receipt, Pharmacokinetics, Pain, Patent, Safety, Anxiety, Sleep apnea, GLOBE, Clinical trial, Inflammatory bowel disease, Concussion, FDA, Â, Pharmaceutical industry, CBD, Hydroxychloroquine

MELBOURNE, Australia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has completed dosing of trial participants in the phase 1 clinical trial undertaken to assess pharmacokinetics and safety of the anti-inflammatory drug IHL-675A.

Key Points: 
  • The Phase 1 trial measured the safety, tolerability, and pharmacokinetic profiles of IHL-675A compared to the reference listed drugs, Epidiolex (CBD) and Plaquenil (HCQ).
  • Three cohorts of 12 participants (n = 36) received either IHL-675A, CBD or HCQ and the clinical assessments were identical across the three arms of the trial.
  • The trial was conducted by CMAX Clinical Research in Adelaide, South Australia and managed by Avance Clinical.
  • Initial reports of drug tolerability afford Incannex the opportunity to proceed with the next stage of development for IHL-675A.

ABQAURP Announces the 2023 CHCQM Diplomate Achievement Award

Retrieved on: 
Thursday, September 15, 2022
Award, American Board of Commissioners for Foreign Missions, NEW, ACCME, Certification, Diplomate of National Board, Leadership, Patient safety, Quality assurance, Conference, HCQ, Medicine, Pharmaceutical industry

NEW PORT RICHIE, Fla., Sept. 15, 2022 /PRNewswire-PRWeb/ -- ABQAURP Diplomates have voluntarily achieved certification in Health Care Quality and Management (CHCQM); demonstrating commitment to patient safety, health care quality, and effective care. ABQAURP's long-standing membership attests to the value certification brings throughout your health care career.

Key Points: 
  • The American Board of Quality Assurance and Utilization Review Physicians (ABQAURP) is now accepting applications for the CHCQM Diplomate Achievement Award to recognize the achievements of Diplomates in the fields of health care quality and patient safety.
  • NEW PORT RICHIE, Fla., Sept. 15, 2022 /PRNewswire-PRWeb/ -- ABQAURP Diplomates have voluntarily achieved certification in Health Care Quality and Management (CHCQM) ; demonstrating commitment to patient safety, health care quality, and effective care.
  • To recognize the achievements of Diplomates with outstanding initiatives in health care quality and patient safety that have led to measurable improvements in the advancement of the field, ABQAURP presents the CHCQM Diplomate Achievement Award bi-annually in conjunction with the Annual Health Care Quality & Patient Safety Conference (HCQ&PS).
  • The Award will be presented at the 46th Annual Health Care Quality & Patient Safety Conference on October 19-20, 2023, in Clearwater Beach, FL.

BioMed Valley Discoveries Announces First Patient Dosed in Phase II Combination Trial with Ulixertinib (BVD-523), its First-in-Class and Best-in-Class ERK Inhibitor, in Combination with Hydroxychloroquine

Retrieved on: 
Monday, September 12, 2022
Institute, Stowers Institute for Medical Research, MAPK, Autophagy, Phase, American Century, Neoplasm, Century, University, Investment, BRAF, Hydroxychloroquine, ERK2, Survival, ERK, Patient, Clinical trial, BVD, Huntsman Cancer Institute, Medical research, Tumor microenvironment, HCQ, ERK1, American Century Companies, Mutation, Pharmaceutical industry

KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).

Key Points: 
  • KANSAS CITY, Mo., Sept. 12, 2022 /PRNewswire/ -- BioMed Valley Discoveries (BVD) announced that the first patient has been dosed in a phase II clinical trial of ulixertinib (BVD-523) in combination with hydroxychloroquine (HCQ).
  • Ulixertinib is a first-in-class and best-in-class ERK inhibitor, with this clinical trial focusing on patients with advanced gastrointestinal malignancies and mutations in the MAPK pathway.
  • Previous efforts have also established a recommended phase 2 dose in combination with palbociclib, with additional combination efforts ongoing.
  • About BioMed Valley Discoveries (BVD): BioMed Valley Discoveries is a clinical stage biotechnology company focused on addressing unmet medical needs in a variety of therapeutic and diagnostic areas.